The Relationship Between Hematocrit Levels With Major Cardiovascular Events In Acute Myocardial Infarction Patients At Adam Malik Haji Hospital Medan

Feb 27, 2025 by ADMIN 150 views

The Relationship Between Hematocrit Levels and Major Cardiovascular Events in Acute Myocardial Infarction Patients at Adam Malik Haji Hospital Medan

Introduction

Acute myocardial infarction (AMI) is a serious medical condition that can lead to major cardiovascular (KKM) events, which can be life-threatening. Despite adequate treatment, the incidence of KKM events remains high in patients with AMI. One of the parameters that can be used to predict the risk of KKM events is the hematocrit level when the patient is hospitalized. This study aims to explore whether there is a significant relationship between hematocrit levels and KKM events in AMI patients at Adam Malik Haji Hospital Medan.

Background

AMI is a condition where the blood flow to the heart is blocked, causing damage to the heart muscle. This can lead to complications such as congestive heart failure, arrhythmias, cardiogenic shock, and even death. The hematocrit level is a measure of the proportion of red blood cells in the blood, and it is often used as a predictor of prognosis in various cardiovascular conditions. However, the relationship between hematocrit levels and KKM events in AMI patients is not well understood.

Research Methods

This study used an analytic design with the latitude cutting method, which was carried out at the Adam Malik Medan Hajj Hospital between January 1 and December 31, 2016. A total of 232 subjects were selected through the total sampling method of medical record data. The study aimed to explore the relationship between hematocrit levels and KKM events in AMI patients.

Research Results

The results of the study showed that the majority of AMI patients were male (82.8%) with the most age range in groups 51-60 years (43.1%). Univariate analysis showed that 74.1% of patients experienced KKM events during treatment, where congestive heart failure was the most common complication (19%). However, the analysis using the chi-square test showed that there was no significant relationship between hematocrit levels and several types of KKM events such as congestive heart failure (p = 0.646), arrhythmias (p = 0.655), cardiogenic shock (p = 0.486), death (p = 0.963), and KKM as a whole (p = 0.777).

Discussion and Analysis

The results of this study indicate that hematocrit levels cannot be used as effective predictors for the events of KKM in AMI patients at Adam Malik Haji Hospital Medan. Although hematocrit levels are often associated with prognosis in various cardiovascular conditions, in the context of AMI, the data obtained shows that other factors may be more influential. Factors such as age, sex, and other comorbidities such as diabetes mellitus and hypertension can affect the prognosis of AMI patients. Previous studies also show that the patient's systemic conditions, including inflammatory and hemodynamic status, can be more determined to the events of complications compared to hematocrit levels.

Conclusion

From this study, it can be concluded that there is no significant relationship between hematocrit levels and major cardiovascular events in acute myocardial infarction patients at Adam Malik Hajj Hospital Medan. This finding is important to clarify our understanding of risk factors for IMA patients and can be a reference for further deepest research. IMA patient management needs to consider various risk factors to improve clinical outcomes and prevent more serious complications.

Implications for Practice

The findings of this study have several implications for practice. Firstly, healthcare providers should consider other factors such as age, sex, and comorbidities when assessing the risk of KKM events in AMI patients. Secondly, hematocrit levels should not be used as a sole predictor of prognosis in AMI patients. Finally, further research is needed to explore the relationship between hematocrit levels and KKM events in AMI patients.

Limitations of the Study

This study has several limitations. Firstly, the study was conducted at a single hospital, which may limit the generalizability of the findings. Secondly, the study only included patients with AMI, which may not be representative of all patients with cardiovascular disease. Finally, the study only used hematocrit levels as a predictor of prognosis, which may not be the only factor influencing the risk of KKM events.

Future Research Directions

Future research should aim to explore the relationship between hematocrit levels and KKM events in AMI patients in a larger and more diverse population. Additionally, research should focus on identifying other factors that may influence the risk of KKM events in AMI patients. Finally, research should aim to develop more accurate predictors of prognosis in AMI patients.

References

[1] American Heart Association. (2017). Heart Disease and Stroke Statistics—2017 Update. Circulation, 135(10), e146-e603.
[2] Centers for Disease Control and Prevention. (2019). Heart Disease Facts. Retrieved from https://www.cdc.gov/heartdisease/facts.htm
[3] National Institute of Health. (2020). Acute Myocardial Infarction. Retrieved from https://www.nhlbi.nih.gov/health-topics/acute-myocardial-infarction

Keywords

Hematocrit levels
Major cardiovascular events
Acute myocardial infarction
Adam Malik Haji Hospital Medan
Risk factors
Prognosis
Cardiovascular disease
Frequently Asked Questions (FAQs) About the Relationship Between Hematocrit Levels and Major Cardiovascular Events in Acute Myocardial Infarction Patients

Q: What is the relationship between hematocrit levels and major cardiovascular events in acute myocardial infarction patients?

A: The study found that there is no significant relationship between hematocrit levels and major cardiovascular events in acute myocardial infarction patients at Adam Malik Haji Hospital Medan.

Q: What are the implications of this study for healthcare providers?

A: Healthcare providers should consider other factors such as age, sex, and comorbidities when assessing the risk of major cardiovascular events in acute myocardial infarction patients. Hematocrit levels should not be used as a sole predictor of prognosis in acute myocardial infarction patients.

Q: What are the limitations of this study?

A: The study was conducted at a single hospital, which may limit the generalizability of the findings. The study only included patients with acute myocardial infarction, which may not be representative of all patients with cardiovascular disease. The study only used hematocrit levels as a predictor of prognosis, which may not be the only factor influencing the risk of major cardiovascular events.

Q: What are the future research directions for this topic?

A: Future research should aim to explore the relationship between hematocrit levels and major cardiovascular events in acute myocardial infarction patients in a larger and more diverse population. Research should focus on identifying other factors that may influence the risk of major cardiovascular events in acute myocardial infarction patients. Research should aim to develop more accurate predictors of prognosis in acute myocardial infarction patients.

Q: What are the risk factors for major cardiovascular events in acute myocardial infarction patients?

A: The risk factors for major cardiovascular events in acute myocardial infarction patients include age, sex, comorbidities such as diabetes mellitus and hypertension, and systemic conditions such as inflammatory and hemodynamic status.

Q: How can healthcare providers improve clinical outcomes and prevent more serious complications in acute myocardial infarction patients?

A: Healthcare providers can improve clinical outcomes and prevent more serious complications in acute myocardial infarction patients by considering various risk factors, including age, sex, comorbidities, and systemic conditions. Healthcare providers should also use more accurate predictors of prognosis, such as biomarkers and imaging studies, to guide treatment decisions.

Q: What are the potential consequences of not considering hematocrit levels as a predictor of prognosis in acute myocardial infarction patients?

A: The potential consequences of not considering hematocrit levels as a predictor of prognosis in acute myocardial infarction patients include delayed diagnosis and treatment, increased morbidity and mortality, and decreased quality of life.

Q: How can patients and their families contribute to the management of acute myocardial infarction patients?

A: Patients and their families can contribute to the management of acute myocardial infarction patients by being aware of the risk factors for major cardiovascular events, following treatment recommendations, and participating in decision-making about care.

Q: What are the future directions for research on the relationship between hematocrit levels and major cardiovascular events in acute myocardial infarction patients?

Q: How can healthcare providers stay up-to-date with the latest research on the relationship between hematocrit levels and major cardiovascular events in acute myocardial infarction patients?

A: Healthcare providers can stay up-to-date with the latest research on the relationship between hematocrit levels and major cardiovascular events in acute myocardial infarction patients by attending conferences and workshops, reading peer-reviewed journals, and participating in online forums and discussions.

Q: What are the potential benefits of considering hematocrit levels as a predictor of prognosis in acute myocardial infarction patients?

A: The potential benefits of considering hematocrit levels as a predictor of prognosis in acute myocardial infarction patients include improved clinical outcomes, reduced morbidity and mortality, and increased quality of life.

Q: How can healthcare providers balance the need for accurate predictors of prognosis with the need for personalized care in acute myocardial infarction patients?

A: Healthcare providers can balance the need for accurate predictors of prognosis with the need for personalized care in acute myocardial infarction patients by using a combination of biomarkers, imaging studies, and clinical judgment to guide treatment decisions.